Theravance Biopharma, a prominent biopharmaceutical firm, has been making waves with its groundbreaking respiratory medicines, which are developed and distributed across the United States and Europe. The firm's flagship product, YUPELRI, is a once-daily nebulized long-acting muscarinic antagonist, which has been specifically designed to target chronic obstructive pulmonary disease (COPD). Additionally, the company offers Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension, and TRELEGY, a revolutionary medication for the treatment of COPD and asthma. Theravance Biopharma boasts of various strategic partnerships that bolster its research and development capabilities. It has licensing partnerships and collaborations with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. The firm has been consistently contributing to the research and development sector since its incorporation in 2013 and is headquartered in George Town, the Cayman Islands.
Theravance Biopharma's ticker is TBPH
The company's shares trade on the NASDAQ stock exchange
They are based in South San Francisco, California
There are 201-500 employees working at Theravance Biopharma
It is http://www.theravance.com/home
Theravance Biopharma is in the Healthcare sector
Theravance Biopharma is in the Biotechnology industry
The following five companies are Theravance Biopharma's industry peers: